Research Advances in Biomarkers and Prognostic Analysis for Breast Cancer Patients

Yongxi Xu

doi:10.54254/2753-8818/2025.AU28758

Theoretical and Natural ScienceOpen access

Research Advances in Biomarkers and Prognostic Analysis for Breast Cancer Patients

Research Article

Open Access

Research Advances in Biomarkers and Prognostic Analysis for Breast Cancer Patients

Yongxi Xu ^1*

¹ University College London

^*Corresponding author: wegmxuq@ucl.ac.uk

Published on 28 October 2025

TNS Vol.147

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-489-2

ISBN (Online): 978-1-80590-490-8

Download Cover

Abstract

Breast cancer exhibits biological heterogeneity, with prognosis significantly influenced by molecular subtypes, genetic alterations, and treatment types. Through further research, two types of translational biomarkers applicable within breast cancer patients have emerged: 1) pre-treatment tissue-based transcriptomic genes that encode intrinsic tumor biology and 2) post-treatment blood-based MRD markers (ctDNA) that capture residual systemic risk. This review establishes logical connections between these two categories, detailing the process of constructing pathways from treatment plan customization to prognostic follow-up assessment. We used literature analysis and comparative methods to extract key points from three research approaches, including data sources, analytical methods, and conclusions, then synthesized and connected them: a survival ranking of significantly associated genes within chemotherapy-treated ER+/HER2- and basal groups, a multivariable prognostic model constructed based on genes in TCGA dataset and a meta-analysis on ctDNA. We identified gaps between studies, how their findings complement each other, and ultimately provided critical progress toward realizing an implementable, end-to-end clinical treatment pathway: Early decision-making based on prognostic biomarkers, followed by ctDNA-guided dynamic risk assessment.

Keywords:

breast cancer, biomarkers, ctDNA, prognosis outcome

View PDF

References

[1]. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast [Internet]. 2022 Sep; 66(66): 15–23. Available from: https: //www.sciencedirect.com/science/article/pii/S0960977622001448

[2]. Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Experimental Hematology & Oncology [Internet]. 2023 Jan 9; 12(1): 3. Available from: https: //pubmed.ncbi.nlm.nih.gov/36624542/

[3]. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast cancer—epidemiology, Risk factors, classification, Prognostic markers, and Current Treatment Strategies—an Updated Review. Cancers [Internet]. 2021; 13(17): 4287. Available from: https: //pmc.ncbi.nlm.nih.gov/articles/PMC8428369/

[4]. Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Computational and Structural Biotechnology Journal. 2021; 19: 4101–9

[5]. Liu L, Chen Z, Shi W, Liu H, Pang W. Breast cancer survival prediction using seven prognostic biomarker genes. Oncology Letters. 2019 Jul 18

[6]. Papakonstantinou A, Gonzalez NS, Pimentel I, Suñol A, Zamora E, Ortiz C, et al. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. Cancer Treatment Reviews [Internet]. 2022 Mar 1; 104: 102362. Available from: https: //www.sciencedirect.com/science/article/pii/S0305737222000263?via%3Dihub

References

[5]. Liu L, Chen Z, Shi W, Liu H, Pang W. Breast cancer survival prediction using seven prognostic biomarker genes. Oncology Letters. 2019 Jul 18

Cite this article

Xu,Y. (2025). Research Advances in Biomarkers and Prognostic Analysis for Breast Cancer Patients. Theoretical and Natural Science,147,72-76.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-489-2(Print) / 978-1-80590-490-8(Online)

Editor: Alan Wang

Conference website: https://2025.icbiomed.org/auckland.html

Conference date: 17 October 2025

Series: Theoretical and Natural Science

Volume number: Vol.147

ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).